English
简体中文
Total: £ 56.28
Published Date: 2024-12-04 | Pages: 91 | Tables: 163 | Medical Care
The global market for Peptide-Drug Conjugates was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peptide-Drug Conjugates, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peptide-Drug Conjugates by region & country, by Type, and by Application.
The Peptide-Drug Conjugates market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide-Drug Conjugates.
Market Segmentation
By Company
AstraZeneca
Bicycle Therapeutics
Cybrexa Therapeutics
Esperance Pharmaceuticals
Oncopeptides
Pepgen Corporation
Soricimed Biopharma
Theratechnologies
Segment by Type:
Cell-penetrating Peptides (CPPs)
Cell-targeting Peptides (CTPs)
Segment by Application
Carcinoma
Sarcoma
Melanoma
Lymphoma
Leukemia
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Peptide-Drug Conjugates manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Peptide-Drug Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Peptide-Drug Conjugates in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Peptide-Drug Conjugates Product Introduction
1.2 Global Peptide-Drug Conjugates Market Size Forecast
1.3 Peptide-Drug Conjugates Market Trends & Drivers
1.3.1 Peptide-Drug Conjugates Industry Trends
1.3.2 Peptide-Drug Conjugates Market Drivers & Opportunity
1.3.3 Peptide-Drug Conjugates Market Challenges
1.3.4 Peptide-Drug Conjugates Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Peptide-Drug Conjugates Players Revenue Ranking (2023)
2.2 Global Peptide-Drug Conjugates Revenue by Company (2019-2024)
2.3 Key Companies Peptide-Drug Conjugates Manufacturing Base Distribution and Headquarters
2.4 Key Companies Peptide-Drug Conjugates Product Offered
2.5 Key Companies Time to Begin Mass Production of Peptide-Drug Conjugates
2.6 Peptide-Drug Conjugates Market Competitive Analysis
2.6.1 Peptide-Drug Conjugates Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Peptide-Drug Conjugates Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-Drug Conjugates as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cell-penetrating Peptides (CPPs)
3.1.2 Cell-targeting Peptides (CTPs)
3.2 Global Peptide-Drug Conjugates Sales Value by Type
3.2.1 Global Peptide-Drug Conjugates Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Peptide-Drug Conjugates Sales Value, by Type (2019-2030)
3.2.3 Global Peptide-Drug Conjugates Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Carcinoma
4.1.2 Sarcoma
4.1.3 Melanoma
4.1.4 Lymphoma
4.1.5 Leukemia
4.2 Global Peptide-Drug Conjugates Sales Value by Application
4.2.1 Global Peptide-Drug Conjugates Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Peptide-Drug Conjugates Sales Value, by Application (2019-2030)
4.2.3 Global Peptide-Drug Conjugates Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Peptide-Drug Conjugates Sales Value by Region
5.1.1 Global Peptide-Drug Conjugates Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Peptide-Drug Conjugates Sales Value by Region (2019-2024)
5.1.3 Global Peptide-Drug Conjugates Sales Value by Region (2025-2030)
5.1.4 Global Peptide-Drug Conjugates Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Peptide-Drug Conjugates Sales Value, 2019-2030
5.2.2 North America Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Peptide-Drug Conjugates Sales Value, 2019-2030
5.3.2 Europe Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Peptide-Drug Conjugates Sales Value, 2019-2030
5.4.2 Asia Pacific Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Peptide-Drug Conjugates Sales Value, 2019-2030
5.5.2 South America Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Peptide-Drug Conjugates Sales Value, 2019-2030
5.6.2 Middle East & Africa Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Peptide-Drug Conjugates Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Peptide-Drug Conjugates Sales Value
6.3 United States
6.3.1 United States Peptide-Drug Conjugates Sales Value, 2019-2030
6.3.2 United States Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Peptide-Drug Conjugates Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Peptide-Drug Conjugates Sales Value, 2019-2030
6.4.2 Europe Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Peptide-Drug Conjugates Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Peptide-Drug Conjugates Sales Value, 2019-2030
6.5.2 China Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
6.5.3 China Peptide-Drug Conjugates Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Peptide-Drug Conjugates Sales Value, 2019-2030
6.6.2 Japan Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Peptide-Drug Conjugates Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Peptide-Drug Conjugates Sales Value, 2019-2030
6.7.2 South Korea Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Peptide-Drug Conjugates Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Peptide-Drug Conjugates Sales Value, 2019-2030
6.8.2 Southeast Asia Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Peptide-Drug Conjugates Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Peptide-Drug Conjugates Sales Value, 2019-2030
6.9.2 India Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
6.9.3 India Peptide-Drug Conjugates Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Profile
7.1.2 AstraZeneca Main Business
7.1.3 AstraZeneca Peptide-Drug Conjugates Products, Services and Solutions
7.1.4 AstraZeneca Peptide-Drug Conjugates Revenue (US$ Million) & (2019-2024)
7.1.5 AstraZeneca Recent Developments
7.2 Bicycle Therapeutics
7.2.1 Bicycle Therapeutics Profile
7.2.2 Bicycle Therapeutics Main Business
7.2.3 Bicycle Therapeutics Peptide-Drug Conjugates Products, Services and Solutions
7.2.4 Bicycle Therapeutics Peptide-Drug Conjugates Revenue (US$ Million) & (2019-2024)
7.2.5 Bicycle Therapeutics Recent Developments
7.3 Cybrexa Therapeutics
7.3.1 Cybrexa Therapeutics Profile
7.3.2 Cybrexa Therapeutics Main Business
7.3.3 Cybrexa Therapeutics Peptide-Drug Conjugates Products, Services and Solutions
7.3.4 Cybrexa Therapeutics Peptide-Drug Conjugates Revenue (US$ Million) & (2019-2024)
7.3.5 Esperance Pharmaceuticals Recent Developments
7.4 Esperance Pharmaceuticals
7.4.1 Esperance Pharmaceuticals Profile
7.4.2 Esperance Pharmaceuticals Main Business
7.4.3 Esperance Pharmaceuticals Peptide-Drug Conjugates Products, Services and Solutions
7.4.4 Esperance Pharmaceuticals Peptide-Drug Conjugates Revenue (US$ Million) & (2019-2024)
7.4.5 Esperance Pharmaceuticals Recent Developments
7.5 Oncopeptides
7.5.1 Oncopeptides Profile
7.5.2 Oncopeptides Main Business
7.5.3 Oncopeptides Peptide-Drug Conjugates Products, Services and Solutions
7.5.4 Oncopeptides Peptide-Drug Conjugates Revenue (US$ Million) & (2019-2024)
7.5.5 Oncopeptides Recent Developments
7.6 Pepgen Corporation
7.6.1 Pepgen Corporation Profile
7.6.2 Pepgen Corporation Main Business
7.6.3 Pepgen Corporation Peptide-Drug Conjugates Products, Services and Solutions
7.6.4 Pepgen Corporation Peptide-Drug Conjugates Revenue (US$ Million) & (2019-2024)
7.6.5 Pepgen Corporation Recent Developments
7.7 Soricimed Biopharma
7.7.1 Soricimed Biopharma Profile
7.7.2 Soricimed Biopharma Main Business
7.7.3 Soricimed Biopharma Peptide-Drug Conjugates Products, Services and Solutions
7.7.4 Soricimed Biopharma Peptide-Drug Conjugates Revenue (US$ Million) & (2019-2024)
7.7.5 Soricimed Biopharma Recent Developments
7.8 Theratechnologies
7.8.1 Theratechnologies Profile
7.8.2 Theratechnologies Main Business
7.8.3 Theratechnologies Peptide-Drug Conjugates Products, Services and Solutions
7.8.4 Theratechnologies Peptide-Drug Conjugates Revenue (US$ Million) & (2019-2024)
7.8.5 Theratechnologies Recent Developments
8 Industry Chain Analysis
8.1 Peptide-Drug Conjugates Industrial Chain
8.2 Peptide-Drug Conjugates Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Peptide-Drug Conjugates Sales Model
8.5.2 Sales Channel
8.5.3 Peptide-Drug Conjugates Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Peptide-Drug Conjugates Market Trends
Table 2. Peptide-Drug Conjugates Market Drivers & Opportunity
Table 3. Peptide-Drug Conjugates Market Challenges
Table 4. Peptide-Drug Conjugates Market Restraints
Table 5. Global Peptide-Drug Conjugates Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Peptide-Drug Conjugates Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Peptide-Drug Conjugates Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Peptide-Drug Conjugates Product Type
Table 9. Key Companies Time to Begin Mass Production of Peptide-Drug Conjugates
Table 10. Global Peptide-Drug Conjugates Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-Drug Conjugates as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Peptide-Drug Conjugates Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Peptide-Drug Conjugates Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Peptide-Drug Conjugates Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Peptide-Drug Conjugates Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Peptide-Drug Conjugates Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Peptide-Drug Conjugates Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Peptide-Drug Conjugates Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Peptide-Drug Conjugates Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Peptide-Drug Conjugates Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Peptide-Drug Conjugates Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Peptide-Drug Conjugates Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Peptide-Drug Conjugates Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Peptide-Drug Conjugates Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Peptide-Drug Conjugates Sales Value by Region (2019-2024) & (%)
Table 27. Global Peptide-Drug Conjugates Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Peptide-Drug Conjugates Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Peptide-Drug Conjugates Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Peptide-Drug Conjugates Sales Value, (2025-2030) & (US$ Million)
Table 31. AstraZeneca Basic Information List
Table 32. AstraZeneca Description and Business Overview
Table 33. AstraZeneca Peptide-Drug Conjugates Products, Services and Solutions
Table 34. Revenue (US$ Million) in Peptide-Drug Conjugates Business of AstraZeneca (2019-2024)
Table 35. AstraZeneca Recent Developments
Table 36. Bicycle Therapeutics Basic Information List
Table 37. Bicycle Therapeutics Description and Business Overview
Table 38. Bicycle Therapeutics Peptide-Drug Conjugates Products, Services and Solutions
Table 39. Revenue (US$ Million) in Peptide-Drug Conjugates Business of Bicycle Therapeutics (2019-2024)
Table 40. Bicycle Therapeutics Recent Developments
Table 41. Cybrexa Therapeutics Basic Information List
Table 42. Cybrexa Therapeutics Description and Business Overview
Table 43. Cybrexa Therapeutics Peptide-Drug Conjugates Products, Services and Solutions
Table 44. Revenue (US$ Million) in Peptide-Drug Conjugates Business of Cybrexa Therapeutics (2019-2024)
Table 45. Cybrexa Therapeutics Recent Developments
Table 46. Esperance Pharmaceuticals Basic Information List
Table 47. Esperance Pharmaceuticals Description and Business Overview
Table 48. Esperance Pharmaceuticals Peptide-Drug Conjugates Products, Services and Solutions
Table 49. Revenue (US$ Million) in Peptide-Drug Conjugates Business of Esperance Pharmaceuticals (2019-2024)
Table 50. Esperance Pharmaceuticals Recent Developments
Table 51. Oncopeptides Basic Information List
Table 52. Oncopeptides Description and Business Overview
Table 53. Oncopeptides Peptide-Drug Conjugates Products, Services and Solutions
Table 54. Revenue (US$ Million) in Peptide-Drug Conjugates Business of Oncopeptides (2019-2024)
Table 55. Oncopeptides Recent Developments
Table 56. Pepgen Corporation Basic Information List
Table 57. Pepgen Corporation Description and Business Overview
Table 58. Pepgen Corporation Peptide-Drug Conjugates Products, Services and Solutions
Table 59. Revenue (US$ Million) in Peptide-Drug Conjugates Business of Pepgen Corporation (2019-2024)
Table 60. Pepgen Corporation Recent Developments
Table 61. Soricimed Biopharma Basic Information List
Table 62. Soricimed Biopharma Description and Business Overview
Table 63. Soricimed Biopharma Peptide-Drug Conjugates Products, Services and Solutions
Table 64. Revenue (US$ Million) in Peptide-Drug Conjugates Business of Soricimed Biopharma (2019-2024)
Table 65. Soricimed Biopharma Recent Developments
Table 66. Theratechnologies Basic Information List
Table 67. Theratechnologies Description and Business Overview
Table 68. Theratechnologies Peptide-Drug Conjugates Products, Services and Solutions
Table 69. Revenue (US$ Million) in Peptide-Drug Conjugates Business of Theratechnologies (2019-2024)
Table 70. Theratechnologies Recent Developments
Table 71. Key Raw Materials Lists
Table 72. Raw Materials Key Suppliers Lists
Table 73. Peptide-Drug Conjugates Downstream Customers
Table 74. Peptide-Drug Conjugates Distributors List
Table 75. Research Programs/Design for This Report
Table 76. Key Data Information from Secondary Sources
Table 77. Key Data Information from Primary Sources
Table 78. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Peptide-Drug Conjugates Product Picture
Figure 2. Global Peptide-Drug Conjugates Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Peptide-Drug Conjugates Sales Value (2019-2030) & (US$ Million)
Figure 4. Peptide-Drug Conjugates Report Years Considered
Figure 5. Global Peptide-Drug Conjugates Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Peptide-Drug Conjugates Revenue in 2023
Figure 7. Peptide-Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Cell-penetrating Peptides (CPPs) Picture
Figure 9. Cell-targeting Peptides (CTPs) Picture
Figure 10. Global Peptide-Drug Conjugates Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Peptide-Drug Conjugates Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Carcinoma
Figure 13. Product Picture of Sarcoma
Figure 14. Product Picture of Melanoma
Figure 15. Product Picture of Lymphoma
Figure 16. Product Picture of Leukemia
Figure 17. Global Peptide-Drug Conjugates Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Peptide-Drug Conjugates Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America Peptide-Drug Conjugates Sales Value (2019-2030) & (US$ Million)
Figure 20. North America Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe Peptide-Drug Conjugates Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific Peptide-Drug Conjugates Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
Figure 25. South America Peptide-Drug Conjugates Sales Value (2019-2030) & (US$ Million)
Figure 26. South America Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa Peptide-Drug Conjugates Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa Peptide-Drug Conjugates Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions Peptide-Drug Conjugates Sales Value (%), (2019-2030)
Figure 30. United States Peptide-Drug Conjugates Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
Figure 32. United States Peptide-Drug Conjugates Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe Peptide-Drug Conjugates Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe Peptide-Drug Conjugates Sales Value by Application (%), 2023 VS 2030
Figure 36. China Peptide-Drug Conjugates Sales Value, (2019-2030) & (US$ Million)
Figure 37. China Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
Figure 38. China Peptide-Drug Conjugates Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan Peptide-Drug Conjugates Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan Peptide-Drug Conjugates Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea Peptide-Drug Conjugates Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea Peptide-Drug Conjugates Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia Peptide-Drug Conjugates Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia Peptide-Drug Conjugates Sales Value by Application (%), 2023 VS 2030
Figure 48. India Peptide-Drug Conjugates Sales Value, (2019-2030) & (US$ Million)
Figure 49. India Peptide-Drug Conjugates Sales Value by Type (%), 2023 VS 2030
Figure 50. India Peptide-Drug Conjugates Sales Value by Application (%), 2023 VS 2030
Figure 51. Peptide-Drug Conjugates Industrial Chain
Figure 52. Peptide-Drug Conjugates Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
